Cereno Scientific Announces FDA-Approved Phase I PK Study of CS014 for PH-ILD Treatment

Cereno Scientific Begins Phase I Study for CS014

Cereno Scientific, a dynamic biotech company dedicated to pioneering treatments for rare cardiovascular and pulmonary diseases, recently received a significant milestone approval from the Swedish Medical Products Agency. This green light enables the company to commence a Phase I pharmacokinetic (PK) study on its novel treatment, CS014. This development is particularly significant as it aligns with feedback obtained during a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA), facilitating a more streamlined approach towards future treatments.

The pharmacokinetic study will involve 14 healthy adult volunteers and is designed as a randomized, open-label, two-period crossover trial. Participants will receive oral doses of CS014 over a week, after which the pharmacokinetics of this novel compound will be compared against valproic acid (VPA), a known histone deacetylase (HDAC) inhibitor. A key objective of the study is to analyze the total and unbound plasma concentrations of CS014 upon reaching a steady state when compared with VPA.

CEO Sten R. Sörensen emphasizes that the initiation of this study is crucial for the ongoing development of CS014. Incorporating the FDA’s insights early had allowed Cereno Scientific to create a targeted PK program, which will support their preparation for a Phase IIb study concerning pulmonary hypertension related to interstitial lung disease (PH-ILD) slated for the first quarter of 2027.

The significance of CS014 lies in its design as a precision deuterated HDAC inhibitor. By effectively modulating epigenetic pathways, CS014 targets disease mechanisms such as vascular remodeling and fibrosis—common drivers of cardiopulmonary diseases. The study's results will be critical not only for understanding CS014's safety profile but also for validating its potential as a treatment alternative in a field where the options are limited.

Upon favorable completion of this study, Cereno expects to eliminate the necessity of additional nonclinical safety assessments and a Phase IIa trial, propelling them straight into Phase IIb preparations. Rahul Agrawal, Chief Medical Officer at Cereno Scientific, shares the excitement about leveraging extensive clinical data from VPA to enhance the safety framework of CS014 while pushing forward its development in the context of a serious and presently inadequately addressed medical condition.

The Phase I trial's outcomes are projected to be available by mid-2026. Given the promising attributes of CS014, this undertaking signifies a strategic and regulatory aligned step towards eventual market approval, embodying Cereno's commitment to innovate and provide much-needed solutions for patients.

Cereno Scientific’s approach encompasses not just CS014 but a broader ambition to address significant unmet medical needs in cardiovascular and pulmonary disease treatments. Their lead candidate, CS1, which showcases similar therapeutic innovation, is already demonstrating a favorable safety profile and efficacy signals in Phase IIa trials.

Set in Gothenburg, Sweden, Cereno Scientific operates with a substantial focus on advancing high-potential drug candidates designed to improve patients' quality of life. With this new FDA-approved study, they remain firmly on track to transform hope into reality for individuals suffering from rare and severe health conditions, emphasizing their vision to enhance and extend life.